Here's why Cologuard's popularity will continue to climb for a long time.
These three marijuana stocks have underperformed in 2019, and investors want to know if they'll return to their former glory.
Which Canadian cannabis producer has what it takes to bounce back from recent disappointments?
The reaction to Aphria's latest earnings call may have created a bargain opportunity.
A big investment bank finally weighed in on marijuana stocks, and it likes what it sees in HEXO.
Fear of political headwinds that have been hammering health insurers has spread to the hospital operators that depend on them.
Everything's falling into place for the pioneer of RNA interference.
Mid-stage clinical trial results weren't what some investors were looking for.
For real earnings, you need to head south of the border.
The complete presentation of results from the Regenerate trial wasn't exactly what investors were expecting.
Find out how shares of these biopharmaceutical companies outperformed for some lucky investors with great timing.
Spinning off a less-than-thrilling eye care business isn't the only reason.
A failed forward trial forced the biotech to take big steps back.
Results from a mid-stage study with a potential new eczema drug gave investors a reason to cheer.
It looks like the company found an easy solution to a big problem.
This tiny biotech may have found the tastiest low-hanging fruit the industry's ever seen.
These two are intertwined in a legal tango that could get messy.
Despite signs of a slowdown, Constellation Brands' CEO is still confident about blazing fast sales growth from his company's new partner.
The biotech giant's most important drug is under a microscope and it doesn't look pretty.
Are intrepid short-sellers taking advantage of misguided enthusiasm?